PACS Quote, Financials, Valuation and Earnings

Ensign Group has a net margin of -1.11% compared to PACS Group's net margin of 7.25%. PACS Group's return on equity of -- beat Ensign Group's return on equity of 15.07%.

PACS Group has a consensus price target of $34.83, signalling upside risk potential of 167.74%. On the other hand Ensign Group has an analysts' consensus of $169.50 which suggests that it could grow by 26.05%. Given that PACS Group has higher upside potential than Ensign Group, analysts believe PACS Group is more attractive than Ensign Group.

PACS Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ensign Group has a beta of 0.918, suggesting its less volatile than the S&P 500 by 8.238%.

PACS Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ensign Group offers a yield of 0.18% to investors and pays a quarterly dividend of $0.06 per share. PACS Group pays 71.23% of its earnings as a dividend. Ensign Group pays out 6.16% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

PACS Group quarterly revenues are $981.8M, which are smaller than Ensign Group quarterly revenues of $1.1B. PACS Group's net income of -$10.9M is lower than Ensign Group's net income of $78.4M. Notably, PACS Group's price-to-earnings ratio is 19.89x while Ensign Group's PE ratio is 32.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PACS Group is 0.57x versus 1.90x for Ensign Group. Usually stocks with elevated PS ratios are considered overvalued.

Guardian Pharmacy Services has a net margin of -1.11% compared to PACS Group's net margin of -38.8%. PACS Group's return on equity of -- beat Guardian Pharmacy Services's return on equity of -109.2%.

PACS Group has a consensus price target of $34.83, signalling upside risk potential of 167.74%. On the other hand Guardian Pharmacy Services has an analysts' consensus of -- which suggests that it could grow by 12.1%. Given that PACS Group has higher upside potential than Guardian Pharmacy Services, analysts believe PACS Group is more attractive than Guardian Pharmacy Services.

PACS Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Guardian Pharmacy Services has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PACS Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardian Pharmacy Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PACS Group pays 71.23% of its earnings as a dividend. Guardian Pharmacy Services pays out 160.75% of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Guardian Pharmacy Services's is not.

PACS Group quarterly revenues are $981.8M, which are larger than Guardian Pharmacy Services quarterly revenues of $314.4M. PACS Group's net income of -$10.9M is higher than Guardian Pharmacy Services's net income of -$122M. Notably, PACS Group's price-to-earnings ratio is 19.89x while Guardian Pharmacy Services's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PACS Group is 0.57x versus 1.13x for Guardian Pharmacy Services. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of -1.11% compared to PACS Group's net margin of -1.91%. PACS Group's return on equity of -- beat LifeStance Health Group's return on equity of -6.64%.

PACS Group has a consensus price target of $34.83, signalling upside risk potential of 167.74%. On the other hand LifeStance Health Group has an analysts' consensus of -- which suggests that it could grow by 19.18%. Given that PACS Group has higher upside potential than LifeStance Health Group, analysts believe PACS Group is more attractive than LifeStance Health Group.

PACS Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PACS Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PACS Group pays 71.23% of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PACS Group quarterly revenues are $981.8M, which are larger than LifeStance Health Group quarterly revenues of $312.7M. PACS Group's net income of -$10.9M is lower than LifeStance Health Group's net income of -$6M. Notably, PACS Group's price-to-earnings ratio is 19.89x while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PACS Group is 0.57x versus 2.28x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

Pennant Group has a net margin of -1.11% compared to PACS Group's net margin of 3.43%. PACS Group's return on equity of -- beat Pennant Group's return on equity of 13.06%.

PACS Group has a consensus price target of $34.83, signalling upside risk potential of 167.74%. On the other hand Pennant Group has an analysts' consensus of $37.20 which suggests that it could grow by 35.87%. Given that PACS Group has higher upside potential than Pennant Group, analysts believe PACS Group is more attractive than Pennant Group.

PACS Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pennant Group has a beta of 1.951, suggesting its more volatile than the S&P 500 by 95.085%.

PACS Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pennant Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PACS Group pays 71.23% of its earnings as a dividend. Pennant Group pays out -- of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PACS Group quarterly revenues are $981.8M, which are larger than Pennant Group quarterly revenues of $180.7M. PACS Group's net income of -$10.9M is lower than Pennant Group's net income of $6.2M. Notably, PACS Group's price-to-earnings ratio is 19.89x while Pennant Group's PE ratio is 40.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PACS Group is 0.57x versus 1.29x for Pennant Group. Usually stocks with elevated PS ratios are considered overvalued.